EA033083B1 - Циклические соединения - Google Patents

Циклические соединения

Info

Publication number
EA033083B1
EA033083B1 EA201792469A EA201792469A EA033083B1 EA 033083 B1 EA033083 B1 EA 033083B1 EA 201792469 A EA201792469 A EA 201792469A EA 201792469 A EA201792469 A EA 201792469A EA 033083 B1 EA033083 B1 EA 033083B1
Authority
EA
Eurasian Patent Office
Prior art keywords
chemotherapy
relates
present
cyclic compounds
induced
Prior art date
Application number
EA201792469A
Other languages
English (en)
Other versions
EA201792469A1 (ru
Inventor
Тоситаке Кобаяси
Морихиса Сайтох
Ясуфуми Вада
Хироси Нара
Нобуюки Негоро
Тайсуке Катох
Масаси Ямасаки
Такахиро ТАНАКА
Наоми Китамото
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201792469A1 publication Critical patent/EA201792469A1/ru
Publication of EA033083B1 publication Critical patent/EA033083B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/12—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

Изобретение относится к соединениям, обладающим ингибирующей активностью в отношении Toll-подобного рецептора 4 (TLR4), которые полезны в качестве профилактических и терапевтических лекарственных средств при воспалительном заболевании и/или заболевании центральной нервной системы или при заболеваниях, таких как вызванная химиотерапией периферическая невропатия (CIPN), вызванная химиотерапией невропатическая боль (CINP), повреждение печени и/или ишемически-реперфузионное повреждение (IRI) и т.п. Настоящее изобретение относится к соединению, представленному формулой (I), и его соли, где каждый символ более подробно раскрыт в описании
EA201792469A 2015-05-08 2016-05-06 Циклические соединения EA033083B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015095817 2015-05-08
PCT/JP2016/064204 WO2016182036A1 (en) 2015-05-08 2016-05-06 Cyclic compounds

Publications (2)

Publication Number Publication Date
EA201792469A1 EA201792469A1 (ru) 2018-06-29
EA033083B1 true EA033083B1 (ru) 2019-08-30

Family

ID=56132991

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792469A EA033083B1 (ru) 2015-05-08 2016-05-06 Циклические соединения

Country Status (12)

Country Link
US (3) US9611244B2 (ru)
EP (1) EP3294706B1 (ru)
JP (1) JP6718884B2 (ru)
CN (1) CN107835800B (ru)
AR (1) AR104539A1 (ru)
BR (1) BR112017023818A2 (ru)
CA (1) CA2985325C (ru)
EA (1) EA033083B1 (ru)
ES (1) ES2772703T3 (ru)
TW (1) TW201704206A (ru)
UY (1) UY36675A (ru)
WO (1) WO2016182036A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201704206A (zh) * 2015-05-08 2017-02-01 武田藥品工業股份有限公司 環狀化合物
RU2742337C2 (ru) 2016-09-09 2021-02-04 Такеда Фармасьютикал Компани Лимитед Циклическое соединение
FR3095755A1 (fr) * 2019-05-10 2020-11-13 Balmes Transplantation Nouveaux médicaments cytoprotecteurs
CN114425054A (zh) * 2022-01-20 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1495756A1 (en) * 2002-04-08 2005-01-12 Takeda Chemical Industries, Ltd. Severe sepsis preventive therapeutic agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100577044B1 (ko) 1998-03-09 2006-05-08 다케다 야쿠힌 고교 가부시키가이샤 시클로알켄 유도체, 그의 제조 방법 및 용도
DE60045033D1 (de) * 1999-08-06 2010-11-11 Takeda Pharmaceutical Substituierte aromatische ringverbindungen, verfahren zu ihrer herstellung und ihre anwendung
JP2004002370A (ja) * 2002-04-08 2004-01-08 Takeda Chem Ind Ltd 重症セプシス予防治療剤
CN101309900B (zh) * 2005-09-14 2015-04-22 第一三共株式会社 取代环烯烃衍生物
JP2008260760A (ja) 2007-03-12 2008-10-30 Daiichi Sankyo Co Ltd 置換シクロアルケン誘導体を含有する医薬組成物
US20100135908A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
JP6131046B2 (ja) 2010-01-27 2017-05-17 武田薬品工業株式会社 抗癌剤により誘発される末梢神経障害を抑制する化合物
TW201704206A (zh) * 2015-05-08 2017-02-01 武田藥品工業股份有限公司 環狀化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1495756A1 (en) * 2002-04-08 2005-01-12 Takeda Chemical Industries, Ltd. Severe sepsis preventive therapeutic agent

Also Published As

Publication number Publication date
EP3294706A1 (en) 2018-03-21
CN107835800B (zh) 2019-11-26
US9828357B2 (en) 2017-11-28
EP3294706B1 (en) 2019-12-04
US20160326102A1 (en) 2016-11-10
CN107835800A (zh) 2018-03-23
US9533966B2 (en) 2017-01-03
ES2772703T3 (es) 2020-07-08
US20160326133A1 (en) 2016-11-10
US20170066737A1 (en) 2017-03-09
WO2016182036A1 (en) 2016-11-17
JP6718884B2 (ja) 2020-07-08
AR104539A1 (es) 2017-07-26
BR112017023818A2 (pt) 2018-07-31
EA201792469A1 (ru) 2018-06-29
TW201704206A (zh) 2017-02-01
CA2985325A1 (en) 2016-11-17
UY36675A (es) 2016-12-30
US9611244B2 (en) 2017-04-04
JP2018516875A (ja) 2018-06-28
CA2985325C (en) 2023-09-26

Similar Documents

Publication Publication Date Title
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
CR20200617A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
MX368781B (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
MX2016002238A (es) Alcoholes de alquilino y metodos de uso.
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
PH12019501811A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
EA033083B1 (ru) Циклические соединения
EA201992542A1 (ru) Фармацевтическая композиция для местного применения, содержащая, по меньшей мере, амитриптилин, для лечения периферической нейропатической боли
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
NZ726695A (en) Gls1 inhibitors for treating disease
UA117154C2 (uk) Антагоністи s1p3
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
PH12016502568A1 (en) Novel heterocyclic compound
MX2019012522A (es) Compuestos y metodos terapeuticos.
WO2015001541A3 (en) Pharmaceutical film composition
PH12017501336A1 (en) Preventive and/or therapeutic agent of immune disease
MY197042A (en) Compounds
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM